Chiesi Farmaceutici has licenced commercialiation rights for LHON treatment Raxone (idebenone) from Santhera Pharmaceuticals for CHF50m (€44m) in cash plus sales milestones.
EU agriculture ministers want to exclude crops created by targeted mutation methods from EU GMO legislation.
Evotec SE is set to acquire biologics manufacturing specialist Just Biotherapeutics, Inc in a deal that could amount up to $90m.
Mogrify appoints 15 new staff including, Dr Karin Schmitt as Chief Business Officer and Joe Foster as Chief Operating Officer
Researchers at German regulatory authority Paul-Ehrlich Institute (PEI) have patented a method to accurately forecast biotech-based protein synthesis in host cells.
In an oversubscribed Series B round led by LSP, Paris-based DNA Script raised US$38.5. Bpifrance and existing investors Illumina Ventures, M. Ventures, Sofinnova Partners, Kurma Partners and Idinvest Partners contributed.
Although the Swiss biotech sector continues to grow and the annual Swiss Biotech Day is as sought-after as never before, panelists and attendees remain cautious with their predictions. A reoccurring theme at the event in Basel was the plea for change.
There is a growing demand for more patient-centric drug delivery and improved health-care cost management via self-administration and smart devices. The global drug device combination market is projected to reach nearly US$140m by 2025. It’s where the two different worlds of pharmaceutical (GMP) and standardised medical devices collide.Each needs to learn from the other in order to facilitate the regulation process in Europe.
Researchers from Universities Nijmegen and Naples have presented a retinal AAV-based gene therapy delivery system that can express huge genetic elements by assembling protein fragments from several vectors.
Bionure, a biotech company specialized in neuroprotection, today announces that it has appointed Dr. Lucia Septien as chief medical officer.